Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nab-Paclitaxel plus Gemcitabine and FOLFOX in Metastatic Pancreatic Cancer.
Carrato A, Pazo-Cid R, Macarulla T, Gallego J, Jiménez-Fonseca P, Rivera F, Cano MT, Rodriguez-Garrote M, Pericay C, Alés I, Layos L, Graña B, Iranzo V, Gallego I, Garcia-Carbonero R, de Mena IR, Guillén-Ponce C, Aranda E. Carrato A, et al. Among authors: cano mt. NEJM Evid. 2024 Feb;3(2):EVIDoa2300144. doi: 10.1056/EVIDoa2300144. Epub 2024 Jan 23. NEJM Evid. 2024. PMID: 38320486 Clinical Trial.
Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy.
Vidal J, Bellosillo B, Santos Vivas C, García-Alfonso P, Carrato A, Cano MT, García-Carbonero R, Élez E, Losa F, Massutí B, Valladares-Ayerbes M, Viéitez JM, Manzano JL, Azuara D, Gallego J, Pairet S, Capellá G, Salazar R, Tabernero J, Aranda E, Montagut C. Vidal J, et al. Among authors: cano mt. Ann Oncol. 2019 Mar 1;30(3):439-446. doi: 10.1093/annonc/mdz005. Ann Oncol. 2019. PMID: 30689692 Free article.
Tumour location and efficacy of first-line EGFR inhibitors in KRAS/RAS wild-type metastatic colorectal cancer: retrospective analyses of two phase II randomised Spanish TTD trials.
Benavides M, Díaz-Rubio E, Carrato A, Abad A, Guillén C, Garcia-Alfonso P, Gil S, Cano MT, Safont MJ, Gravalos C, Manzano JL, Sánchez A, Alcaide J, López R, Massutí B, Sastre J, Martínez E, Escudero P, Méndez M, Aranda E. Benavides M, et al. Among authors: cano mt. ESMO Open. 2019 Dec 1;4(6):e000599. doi: 10.1136/esmoopen-2019-000599. eCollection 2019. ESMO Open. 2019. PMID: 31803504 Free PMC article. Clinical Trial.
Circulating Cell-Free DNA-Based Liquid Biopsy Markers for the Non-Invasive Prognosis and Monitoring of Metastatic Pancreatic Cancer.
Toledano-Fonseca M, Cano MT, Inga E, Rodríguez-Alonso R, Gómez-España MA, Guil-Luna S, Mena-Osuna R, de la Haba-Rodríguez JR, Rodríguez-Ariza A, Aranda E. Toledano-Fonseca M, et al. Among authors: cano mt. Cancers (Basel). 2020 Jul 1;12(7):1754. doi: 10.3390/cancers12071754. Cancers (Basel). 2020. PMID: 32630266 Free PMC article.
Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study.
Sastre J, García-Alfonso P, Viéitez JM, Cano MT, Rivera F, Reina-Zoilo JJ, Salud-Salvia A, Quintero G, Robles-Díaz L, Safont MJ, La Casta A, Gil S, Polo E, Asensio-Martínez E, García-Paredes B, López RL, Guillot M, Valladares-Ayerbes M, Aranda E, Díaz-Rubio E; Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD). Sastre J, et al. Among authors: cano mt. ESMO Open. 2021 Apr;6(2):100062. doi: 10.1016/j.esmoop.2021.100062. Epub 2021 Mar 10. ESMO Open. 2021. PMID: 33711671 Free PMC article. Clinical Trial.
The Combination of Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio with Liquid Biopsy Biomarkers Improves Prognosis Prediction in Metastatic Pancreatic Cancer.
Toledano-Fonseca M, Cano MT, Inga E, Gómez-España A, Guil-Luna S, García-Ortiz MV, Mena-Osuna R, De la Haba-Rodriguez JR, Rodríguez-Ariza A, Aranda E. Toledano-Fonseca M, et al. Among authors: cano mt. Cancers (Basel). 2021 Mar 10;13(6):1210. doi: 10.3390/cancers13061210. Cancers (Basel). 2021. PMID: 33802006 Free PMC article.
Basal VEGF-A and ACE Plasma Levels of Metastatic Colorectal Cancer Patients Have Prognostic Value for First-Line Treatment with Chemotherapy Plus Bevacizumab.
Ortiz-Morales MJ, Toledano-Fonseca M, Mena-Osuna R, Cano MT, Gómez-España A, Haba-Rodríguez JR, Rodríguez-Ariza A, Aranda E. Ortiz-Morales MJ, et al. Among authors: cano mt. Cancers (Basel). 2022 Jun 21;14(13):3054. doi: 10.3390/cancers14133054. Cancers (Basel). 2022. PMID: 35804826 Free PMC article.
Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study.
Vidal J, Fernández-Rodríguez MC, Casadevall D, García-Alfonso P, Páez D, Guix M, Alonso V, Cano MT, Santos C, Durán G, Elez E, Manzano JL, Garcia-Carbonero R, Ferreiro R, Losa F, Pineda E, Sastre J, Rivera F, Bellosillo B, Tabernero J, Aranda E, Salazar R, Montagut C; Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD). Vidal J, et al. Among authors: cano mt. Clin Cancer Res. 2023 Jan 17;29(2):379-388. doi: 10.1158/1078-0432.CCR-22-1696. Clin Cancer Res. 2023. PMID: 36074154
A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial).
Argilés G, Mulet N, Valladares-Ayerbes M, Viéitez JM, Grávalos C, García-Alfonso P, Santos C, Tobeña M, García-Paredes B, Benavides M, Cano MT, Loupakis F, Rodríguez-Garrote M, Rivera F, Goldberg RM, Cremolini C, Bennouna J, Ciardiello F, Tabernero JM, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD) and UNICANCER GI; The, REARRANGE investigators; Principal investigator; Argilés G, Tabernero J; Steering Committee; Investigators. Argilés G, et al. Among authors: cano mt. Eur J Cancer. 2022 Dec;177:154-163. doi: 10.1016/j.ejca.2022.09.037. Epub 2022 Oct 14. Eur J Cancer. 2022. PMID: 36335783 Free article. Clinical Trial.
Circulating NPTX2 methylation as a non-invasive biomarker for prognosis and monitoring of metastatic pancreatic cancer.
García-Ortiz MV, Cano-Ramírez P, Toledano-Fonseca M, Cano MT, Inga-Saavedra E, Rodríguez-Alonso RM, Guil-Luna S, Gómez-España MA, Rodríguez-Ariza A, Aranda E. García-Ortiz MV, et al. Among authors: cano mt. Clin Epigenetics. 2023 Jul 22;15(1):118. doi: 10.1186/s13148-023-01535-4. Clin Epigenetics. 2023. PMID: 37481552 Free PMC article.
20 results